Necrostatin1 alleviates temporomandibular joint osteoarthritis in rats
Temporomandibular joint osteoarthritis (TMJ-OA) is a prevalent oral and maxillofacial disorder characterized by a complex etiology and pathogenesis. Targeting and eliminating senescent chondrocytes is emerging as a promising therapeutic strategy for TMJ-OA. Necrostatin-1 (NEC1), a receptor-interacting protein kinase 1 (RIPK1)-targeted necroptosis inhibitor, has shown potential therapeutic effects in various skeletal disorders. However, the therapeutic implications of NEC1 in TMJ-OA, particularly regarding its effect on chondrocyte senescence, remain unclear. In this study, models of TMJOA were established by utilizing Monosodium iodoacetate (MIA) to induce TMJ-OA in rats 2 weeks. NEC1/NS were administered via intra-articular injection. After experiments the rats condyler samples were collected and for RNA sequencing.